SCHEMBL12604468

SCHEMBL12604468

O=C(Nc1ccc(OC(F)(F)F)cc1)OCCn1ncc2ccccc2c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ MITF O75030 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ TP53 P04637 3/20 0.47
▸ KMT2A Q03164 1/20 0.45
▸ MAPT P10636 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ IGF1R P08069 2/20 0.43
▸ MMP2 P08253 1/20 0.43
▸ MMP3 P08254 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ MMP13 P45452 1/20 0.43
▸ NPBWR1 P48145 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ THRB P10828 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ KCNA5 P22460 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12604467 0.83 RAB9A (0.58) NPC1RAB9AMITFPKMTP53
SCHEMBL7586791 0.79 NPBWR1 (0.48) NPC1RAB9AMITFPKMTP53
SCHEMBL12604465 0.78 NPC1 (0.55) NPC1RAB9AMITFPKMKMT2A
SCHEMBL12604469 0.71 NPC1 (0.48) NPC1RAB9AMITFPKMKMT2A
SCHEMBL9229803 0.69 NPC1 (0.62) NPC1RAB9AMITFPKMTP53
SCHEMBL8117033 0.69 NPC1 (0.69) NPC1RAB9AMITFPKMKMT2A
SCHEMBL5454302 0.68 NPC1 (0.77) NPC1RAB9AMITFPKMKMT2A
SCHEMBL13717574 0.67 NPC1 (0.47) NPC1RAB9AMITFPKMTP53
SCHEMBL13718079 0.67 NPC1 (0.47) NPC1RAB9AMITFPKMTP53
SCHEMBL2098157 0.67 EPHX2 (0.63) RAB9AKMT2AMAPTLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140066486-A1 REL INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-03-06 — — US disclosed
US-20110118325-A1 REL INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2011-05-19 — — US disclosed
US-20110118325-A1 REL INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118325-A1 REL INHIBITORS AND METHODS OF USE THEREOF REL, RCOR3, RBBP4 NPC1 1943/4885RAB9A 2002/4885MITF 423/4885
US-20140066486-A1 REL INHIBITORS AND METHODS OF USE THEREOF REL, RCOR3, RBBP4 NPC1 1943/4885RAB9A 2002/4885MITF 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback